In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) closed the day trading at $12.79 up 0.31% from the previous closing price of $12.75. In other words, the price has increased by $0.31 from its previous closing price. On the day, 1.23 million shares were traded. AVDL stock price reached its highest trading level at $13.0583 during the session, while it also had its lowest trading level at $12.48.
Ratios:
For a better understanding of AVDL, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.23 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 210.85. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 2.79. In the meantime, Its Debt-to-Equity ratio is 0.42 whereas as Long-Term Debt/Eq ratio is at 0.41.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $12.
On June 12, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $27.Rodman & Renshaw initiated its Buy rating on June 12, 2024, with a $27 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 21 ’25 when Palczuk Linda bought 5,000 shares for $7.93 per share. The transaction valued at 39,640 led to the insider holds 67,900 shares of the business.
Thornton Peter J. bought 10,000 shares of AVDL for $80,450 on Jan 13 ’25. The Director now owns 104,055 shares after completing the transaction at $8.04 per share. On Jan 13 ’25, another insider, Ende Eric J, who serves as the Director of the company, bought 30,000 shares for $7.84 each. As a result, the insider paid 235,218 and bolstered with 208,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 1241878272 and an Enterprise Value of 1198374784. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.62 while its Price-to-Book (P/B) ratio in mrq is 13.65. Its current Enterprise Value per Revenue stands at 5.421 whereas that against EBITDA is 3366.221.
Stock Price History:
The Beta on a monthly basis for AVDL is 1.55, which has changed by -0.2124384 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, AVDL has reached a high of $16.84, while it has fallen to a 52-week low of $6.38. The 50-Day Moving Average of the stock is 26.35%, while the 200-Day Moving Average is calculated to be 32.20%.
Shares Statistics:
Over the past 3-months, AVDL traded about 1.33M shares per day on average, while over the past 10 days, AVDL traded about 1294560 shares per day. A total of 96.78M shares are outstanding, with a floating share count of 88.63M. Insiders hold about 8.72% of the company’s shares, while institutions hold 79.32% stake in the company. Shares short for AVDL as of 1752537600 were 12312691 with a Short Ratio of 9.25, compared to 1749772800 on 10615388. Therefore, it implies a Short% of Shares Outstanding of 12312691 and a Short% of Float of 14.840000999999999.
Earnings Estimates
Currently, 5.0 analysts are dedicated to thoroughly evaluating and rating the performance of Avadel Pharmaceuticals plc (AVDL) in the stock market.The consensus estimate for the next quarter is $0.12, with high estimates of $0.16 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.34 and $0.17 for the fiscal current year, implying an average EPS of $0.25. EPS for the following year is $0.85, with 5.0 analysts recommending between $1.21 and $0.49.
Revenue Estimates
7 analysts predict $73.71M in revenue for the current quarter. It ranges from a high estimate of $74.7M to a low estimate of $72.6M. As of the current estimate, Avadel Pharmaceuticals plc’s year-ago sales were $50.02MFor the next quarter, 7 analysts are estimating revenue of $78.68M. There is a high estimate of $80.14M for the next quarter, whereas the lowest estimate is $77.1M.
A total of 7 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $274.9M, while the lowest revenue estimate was $270.4M, resulting in an average revenue estimate of $273.03M. In the same quarter a year ago, actual revenue was $169.12MBased on 8 analysts’ estimates, the company’s revenue will be $354.34M in the next fiscal year. The high estimate is $378.3M and the low estimate is $333.7M.
